Which YC batch was Cisterna Biologics in?

Cisterna Biologics was in Y Combinator's Summer 2022 batch (S22).

Is Cisterna Biologics still active?

Y Combinator lists Cisterna Biologics as active.

Where is Cisterna Biologics based?

Cisterna Biologics lists San Diego, CA, USA as its location on YC's directory.

Cisterna Biologics: YC S22 company, active

Founders

Not read from YC yet; the weekly run fills these in.

Same space

Competitors

Closest in what they build, same category.

Sensible BiotechnologiesS21Unlocking the next generation of mRNA medicinesShared: synthetic biology, biotech, therapeuticsActive
ParcelBioW24Elevated mRNA for transformative medicines.Shared: synthetic biology, biotech, therapeuticsActive

Adjacent

Overlapping tags, a different niche.

SynsoryBioW24"If-then" conditional logic for protein drugsShared: synthetic biology, biotech, therapeuticsActive
Granza BioW24Building programmable therapeutics for the immune systemShared: synthetic biology, biotech, therapeuticsActive
Engage BioW22Potent, durable, and redosable non-viral genetic medicinesShared: synthetic biology, biotech, therapeuticsAcquired
Kopra BioS24Genetically engineered viruses that teach your immune system to kill…Shared: synthetic biology, biotech, therapeuticsActive
Gerostate AlphaS18Developing novel therapeutics for aging and chronic diseaseShared: biotech, therapeuticsInactive

Also from S22

Batchmates in Summer 2022.

About Cisterna Biologics

Founded in 2022 and based in San Diego, California, Cisterna Biologics is a technology company. It aims to solve some of the challenges currently facing the biotech industry to develop mRNA-based therapeutics – quality, quantity, longevity and cost of mRNA. As mRNA technology matures, it becomes imperative that these issues are solved so we can fully explore mRNA's endless possibilities as a therapeutic. Cisterna uses proprietary technologies to either remove a contaminant at its source or replace the source itself. For example, to remove double-stranded RNA (dsRNA), we use ribozymes - molecular scissors - to precisely cut the mRNA at its 3’ end. This assures not only 3’ homogeneity, but also eliminates dsRNA, which are primarily produced due to self-templated additions at the 3’ end. Utilizing a PCR-like system to amplify the DNA template in large quantities eliminates the requirement for plasmid enrichment in bacteria, the prime source of endotoxin contamination. These are just a few examples of Cisterna’s powerful technologies being used to achieve our goal of 10x higher quality mRNA for therapeutic application.

San Diego, CA, USA